Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
IPO Year: 2015
Exchange: NASDAQ
Website: ascendispharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $355.00 | Buy | Citigroup |
| 3/16/2026 | Buy | Jefferies | |
| 1/28/2026 | $342.00 | Overweight | Barclays |
| 11/18/2025 | $255.00 | Peer Perform | Wolfe Research |
| 10/17/2025 | $271.00 | Strong Buy | Raymond James |
| 7/3/2025 | $250.00 | Overweight | Morgan Stanley |
| 5/5/2025 | $250.00 | Equal-Weight → Overweight | Morgan Stanley |
| 4/16/2025 | $205.00 | Outperform | RBC Capital Mkts |
| 1/7/2025 | $196.00 | Buy | UBS |
| 9/5/2024 | $180.00 | Perform → Outperform | Oppenheimer |
Fastest customizable press release news feed in the world
Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA)
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest securities, representing more than 90% of investable
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a
Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems –
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – kidney
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026. "As a leader in rare endocrine diseases, we are committed to sharing comprehensive clinical trial results in peer-reviewed forums that reinforce the transformative potential of our innovative therapies," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis
- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial demonstrated significantly greater annualized growth velocity (AGV) compared to placebo at Week 52, and sustained these growth improvements through up to two years of treatment. The safety profile for this subgroup through up to two years of treatment was similar to the overall population, with a low rate of injection site reactions (ISRs, all mild), no symptomatic hypotension, and no acceleration of
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.asce
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the "notes") (CUSIP No. 04351P AD3 / ISIN No. US04351PAD33) for redemption on May 6, 2026 (the "Redemption Date"). Ascendis' redemption right in respect of the notes arises pursuant to Section 4.03(B) of the indenture (the "Indenture"), dated as of March 29, 2022, between Ascendis and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as a result of the last reported sale price per ordinary share having exceeded 130% of the conversion pric
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
SD - Ascendis Pharma A/S (0001612042) (Filer)
SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $355.00
Jefferies resumed coverage of Ascendis Pharma with a rating of Buy
Barclays initiated coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $342.00
Wolfe Research initiated coverage of Ascendis Pharma with a rating of Peer Perform and set a new price target of $255.00
Raymond James initiated coverage of Ascendis Pharma with a rating of Strong Buy and set a new price target of $271.00
Morgan Stanley resumed coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $250.00
Morgan Stanley upgraded Ascendis Pharma from Equal-Weight to Overweight and set a new price target of $250.00
RBC Capital Mkts initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $205.00
UBS initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $196.00
Oppenheimer upgraded Ascendis Pharma from Perform to Outperform and set a new price target of $180.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
3/A - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
3 - Ascendis Pharma A/S (0001612042) (Issuer)
3 - Ascendis Pharma A/S (0001612042) (Issuer)
3 - Ascendis Pharma A/S (0001612042) (Issuer)
3 - Ascendis Pharma A/S (0001612042) (Issuer)
Live Leadership Updates
TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to
TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company. All matters presented for shareholder approval at the Me
All matters approved by shareholdersTwo new directors elected to the board TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results from the Company's 2022 Annual and Special Shareholders' Meeting (the "Meeting") held on June 29, 2022, in Toronto, Ontario. At the Meeting, shareholders elected new members to the board of directors, among other matters approved. Mark Brennan, Executive Chairman, commented, "We are very pleased with the outcome of the Meeting and welcome Bob Sellers and Chris Jones to the Ascendant Board. They each bring a wealth of knowledge and experienc
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM – COPENHAGEN, Denmark, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 Annual General Meeting (AGM). Michael Wolf Jensen informed the Board of Directors (the Board) that he will not stand for re-election to the Board at the next Annual General Meeting. Mr. Jensen wi
Live finance-specific insights
- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.asce
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in connection with approvalAscendis to host investor conference call Monday, March 2, at 8:00 am ET COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growt
Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma
– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth – All children completed 52 weeks of treatment and remain on therapy in COACH as of today – Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse
– Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. "With our achievements in the third quarter and year to date, Ascendis is making great progress toward achieving Vision 2030. The ongoing strong global launch of YORVIPATH
COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://in
– Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions – Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning –Conference call today at 4:30 pm ET COPENH
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascen
This live feed shows all institutional transactions in real time.
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G - Ascendis Pharma A/S (0001612042) (Subject)